• Iovance Biotherapeutics Reports Second Quarter and First Half ...🔍

Iovance Biotherapeutics Reports Second Quarter and First Half ...

At a Type B Pre-Phase 3 meeting, the FDA provided positive regulatory feedback that the design of the single-arm. Phase 2 IOV-LUN-202 trial may ...